Labetalol S.A.L.F.

Labetalol, the active ingredient in Labetalol S.A.L.F., is a beta blocker (non‑selective) with alpha‑1 blocking activity presented as an injectable solution for intravenous use. It is employed to manage hypertensive emergencies and severe hypertension in adult patients who require rapid blood pressure control.

GNH USA supplies Labetalol S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Labetalol is indicated for conditions involving acute elevation of blood pressure and acts on both beta‑adrenergic and alpha‑1 receptors.

- Hypertensive emergencies: rapid reduction of dangerously high blood pressure to prevent end‑organ damage. - Severe hypertension: sustained control of markedly elevated arterial pressure when oral therapy is insufficient. - Acute peri‑operative hypertension: stabilization of blood pressure during surgical procedures requiring tight hemodynamic management.

Labetalol may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after dose initiation. - Fatigue: generalized tiredness or reduced energy levels. - Nausea: upset stomach, sometimes accompanied by vomiting. - Headache: mild to moderate cranial pain. - Flushing: transient redness of the face or neck. - Nasal congestion: feeling of blocked nasal passages.

Serious or Rare Side Effects: - Severe hypotension: dangerously low blood pressure requiring medical intervention. - Bronchospasm: narrowing of the airways, particularly in patients with asthma. - Cardiac conduction abnormalities: such as heart block or bradyarrhythmias. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, itching, or anaphylaxis. - Acute heart failure: worsening of cardiac function in susceptible individuals.

Before initiating therapy with Labetalol, clinicians should consider several safety measures.

- Blood pressure monitoring: check BP frequently during dose titration. - Hepatic impairment: reduce dose or avoid use in patients with severe liver disease. - Asthma or chronic obstructive pulmonary disease: use cautiously due to beta‑blockade. - Abrupt discontinuation: taper gradually to avoid rebound hypertension. - Concomitant antihypertensives: adjust doses to prevent excessive hypotension. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Labetalol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other antihypertensives (e.g., ACE inhibitors, diuretics): risk of additive hypotension. - Non‑selective beta blockers: may cause excessive beta‑blockade. - Calcium channel blockers (especially verapamil, diltiazem): can lead to profound bradycardia. - MAO inhibitors: increased risk of hypertensive crisis. - Clonidine: abrupt withdrawal may cause severe hypertension.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Anesthetic agents (e.g., halothane): enhanced cardiovascular depression. - Antiarrhythmic drugs (e.g., amiodarone): possible conduction disturbances. - Insulin or oral hypoglycemics: may mask hypoglycemia symptoms. - Antidepressants (e.g., tricyclics): potential additive cardiac effects.